Roflumilast foam study for children with vitiligo
Part of Skin clinical trials.
This study tests a medicated foam (Roflumilast) in children with non-segmental vitiligo to see if it can improve skin color on the face and body. It is for patients aged 2 to 17 with small patches and at least some pigmented hair in the face patches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Ages 2 to 17 years old
- Diagnosis of non-segmental vitiligo for at least 3 months
- Vitiligo covers less than 10% of your body and at least 0.5% on the face
- At least some white patches on the face have colored hair inside them
- No other serious skin conditions that would interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This trial tests an investigational drug called ICP-332 for vitiligo that isn't limited to one area (non-segmental). It aims to see if the drug can help restore skin color. The study is for both adults and teenagers who have had vitiligo for at least 3 months with a certain amount of skin affected.
This trial tests a cream called roflumilast for people with plaque psoriasis on the body and nail psoriasis. It aims to see if the cream safely improves both skin and nails.
This trial tests a medicated foam called roflumilast to treat seborrheic dermatitis, a skin condition that causes redness, itching, and flaking. It may help people who have moderate to severe symptoms on their face, scalp, or body.
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
This study tests whether a new foam treatment (roflumilast) can safely reduce skin rashes, itching, and other skin problems caused by checkpoint inhibitor cancer drugs. If you've developed these skin side effects from immunotherapy, this trial may help ease your symptoms.
Hear when a new Non-segmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.